AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39608999 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil, Rivastigmine, and/or Memantine
Number of subjects: 153
Study 39608999 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-omics technology (whole exome sequencing, shotgun metagenomic sequencing, liquid chromatography with mass spectrometry)
Number of subjects: 153
Study 39609007 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with cerebral palsy (CP)
Number of subjects: 0
Study 39609007 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) peers
Number of subjects: 0
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in winter
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in spring
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor sedentary time in winter
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor sedentary time in spring
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Step count in winter
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Step count in spring
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviours ≥60 min
Number of subjects: 21
Study 39609010 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in sedentary behaviour
Number of subjects: 21
Study 39609020 — intervention group
Group type: EXPERIMENTAL
Intervention: WORK-ON vocational rehabilitation (VR) as an add-on to usual care
Number of subjects: 0
Study 39609020 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39609020 — intervention group
Group type: EXPERIMENTAL
Intervention: WORK-ON VR
Number of subjects: 0
Study 39609026 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 1332
Study 39609026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 1332
Study 39609026 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 1332
Study 39609025 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR assay
Number of subjects: 4800
Study 39609094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg weekly) + standard of care (SOC)
Number of subjects: 148
Study 39609094 — intervention group
Group type: COMPARATOR
Intervention: Placebo + standard of care (SOC)
Number of subjects: 148
Study 39609094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg weekly) continued
Number of subjects: 148
Study 39609094 — intervention group
Group type: COMPARATOR
Intervention: Placebo-to-abatacept switch
Number of subjects: 148
Study 39609094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg weekly) in non-dermatomyositis (DM) group
Number of subjects: 148
Study 39609094 — intervention group
Group type: COMPARATOR
Intervention: Placebo in non-dermatomyositis (DM) group
Number of subjects: 148
Study 39609094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg weekly) in DM group
Number of subjects: 148
Study 39609094 — intervention group
Group type: COMPARATOR
Intervention: Placebo in DM group
Number of subjects: 148
Study 39609274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (0.05 mCi/kg) group
Number of subjects: 22
Study 39609274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (0.1 mCi/kg) group
Number of subjects: 22
Study 39609274 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 39609361 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum iodine concentrations (SIC) in the 1st trimester (T1)
Number of subjects: 1558
Study 39609361 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum iodine concentrations (SIC) in the highest quartile at T1
Number of subjects: 1558
Study 39609361 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum iodine concentrations (SIC)
Number of subjects: 1558
Study 39609453 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 21
Study 39609683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 90
Study 39609683 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 90
Study 39609683 — intervention group
Group type: COMPARATOR
Intervention: Customised diet
Number of subjects: 90
Study 39609729 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior iliac block (AIB)
Number of subjects: 16
Study 39609817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction (CLC)
Number of subjects: 50
Study 39609817 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave compaction (CWC)
Number of subjects: 50
Study 39609817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplasticized gutta-core (TGC)
Number of subjects: 50
Study 39609817 — intervention group
Group type: COMPARATOR
Intervention: All obturation techniques (CLC, CWC, TGC)
Number of subjects: 50
Study 39609822 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg with piperaquine 640 mg
Number of subjects: 24
Study 39609822 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg with piperaquine 960 mg
Number of subjects: 24
Study 39609822 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg with piperaquine 1440 mg
Number of subjects: 24
Study 39609879 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (0.4 mg once daily and 2.4 mg once weekly)
Number of subjects: 300
Study 39609879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 39609879 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (for type 2 diabetes)
Number of subjects: 300
Study 39609879 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (for pre-type 2 diabetes)
Number of subjects: 300
Study 39609879 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (for no diabetes)
Number of subjects: 300
Study 39609928 — intervention group
Group type: EXPERIMENTAL
Intervention: DANE dashboard for monitoring participant recruitment and attrition
Number of subjects: 0
Study 39609928 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency General Surgery (EGS) Delirium Recovery Model
Number of subjects: 0
Study 39610010 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surface treated with implantoplasty (IPS)
Number of subjects: 10
Study 39610010 — intervention group
Group type: COMPARATOR
Intervention: Modified surface (MS)
Number of subjects: 10
Study 39610010 — intervention group
Group type: COMPARATOR
Intervention: Turned surface (TS)
Number of subjects: 10
Study 39610048 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO-based remote symptom management (intervention group)
Number of subjects: 736
Study 39610048 — intervention group
Group type: COMPARATOR
Intervention: Standard PRO measures without alerts (control group)
Number of subjects: 736
Study 39610253 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation
Number of subjects: 0
Study 39610253 — intervention group
Group type: COMPARATOR
Intervention: Knocking out histidine ammonia-lyase
Number of subjects: 0
Study 39610378 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat treatment with normalization of both LNSC and mUFC
Number of subjects: 160
Study 39610378 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat treatment with only mUFC controlled
Number of subjects: 160
Study 39610378 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat treatment with both LNSC and mUFC uncontrolled
Number of subjects: 160
Study 39610378 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat treatment with control of LNSC and/or mUFC
Number of subjects: 160
Study 39610378 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat treatment with both LNSC and mUFC controlled or only mUFC controlled
Number of subjects: 160
Study 39610655 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-BFR (single-chamber blood flow restriction)
Number of subjects: 27
Study 39610655 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-BFR (multi-chambered blood flow restriction)
Number of subjects: 27
Study 39610655 — intervention group
Group type: COMPARATOR
Intervention: N-BFR (no blood flow restriction control)
Number of subjects: 27
Study 39610664 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and home-based rehabilitation
Number of subjects: 92
Study 39610664 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study 39610700 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS (0.8 mA) paired with upper limb rehabilitation
Number of subjects: 8
Study 39610700 — intervention group
Group type: COMPARATOR
Intervention: Control VNS (0.0 mA) paired with upper limb rehabilitation
Number of subjects: 8
Study 39610700 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS (0.8 mA) paired with rehabilitation (after 90 days follow-up for control group)
Number of subjects: 8
Study 39610700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Active VNS and Control VNS)
Number of subjects: 8
Study 39610764 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Diet Quality Index (IDQI) scores from 0 to 1 year of age
Number of subjects: 2613
Study 39610764 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Diet Quality Index (IDQI) scores at age 1
Number of subjects: 2613
Study 39610764 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Diet Quality Index (IDQI) scores
Number of subjects: 2613
Study 39610765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of carbohydrates, calcium, and vitamin D
Number of subjects: 0
Study 39610765 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality as measured by HEI-2020 component scores
Number of subjects: 0
Study 39610765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intake (protein, fat, iron)
Number of subjects: 0
Study 39610761 — intervention group
Group type: EXPERIMENTAL
Intervention: ACQUIRE Therapy
Number of subjects: 20
Study 39610848 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 39610848 — intervention group
Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 0
Study 39610848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39610946 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroscopy-assisted ERCP using motorized spiral enteroscopy
Number of subjects: 0
Study 39610946 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39610971 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, hybrid cardiac rehabilitation model
Number of subjects: 152
Study 39610971 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise alone (control)
Number of subjects: 152
Study 39610994 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise, mindfulness, behaviour change, and pain neuroscience education programme
Number of subjects: 70
Study 39610994 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional full-body muscle strengthening exercise
Number of subjects: 70
Study 39610995 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 weekly supervised sessions: 35 min moderate-intensity treadmill walking + 25 min strength exercises, starting at gestational weeks 12-18)
Number of subjects: 91
Study 39610995 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 91
Study 39611098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential extracorporeal blood purification (EBP) therapies; specific hemofilter prescription, dose, and anticoagulation strategies not detailed.
Number of subjects: 0
Study 39611098 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment based on clinical and molecular data; details on dosage and duration not specified.
Number of subjects: 0
Study 39611098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CRRT prescription; details on dosage and duration not specified.
Number of subjects: 0
Study 39611145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol BCG infection (1 × 10)
Number of subjects: 12
Study 39611252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic T1 times at baseline (559 ms) and at 4 months (542 ms)
Number of subjects: 485
Study 39611252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic tissue alterations determined by T1 mapping
Number of subjects: 485
Study 39611252 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes related to hepatic tissue alterations
Number of subjects: 485
Study 39611310 — intervention group
Group type: EXPERIMENTAL
Intervention: Human neural progenitor cells delivered to the spinal cord
Number of subjects: 0
Study 39611771 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg every 2/4 weeks (SECQ2W/SECQ4W)
Number of subjects: 0
Study 39611771 — intervention group
Group type: COMPARATOR
Intervention: placebo (SECQ2W-R-PBO or SECQ4W-R-PBO)
Number of subjects: 0
Study 39611870 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 4-5 CKD
Number of subjects: 1052
Study 39612012 — intervention group
Group type: EXPERIMENTAL
Intervention: Home parenteral nutrition (HPN)
Number of subjects: 139
Study 39612031 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management (increased from 35.4% before 2013 to 77.7% after 2013)
Number of subjects: 211
Study 39612031 — intervention group
Group type: COMPARATOR
Intervention: Invasive interventions (decreased over time)
Number of subjects: 211
Study 39612031 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate of patients with CHH
Number of subjects: 211
Study 39612206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT)
Number of subjects: 1
Study 39612621 — intervention group
Group type: EXPERIMENTAL
Intervention: (Neo)adjuvant chemotherapy
Number of subjects: 1266
Study 39612652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GFAP-UCH-L1 test
Number of subjects: 1438
Study 39612652 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B test
Number of subjects: 1438
Study 39612700 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA detected at surgery
Number of subjects: 41
Study 39612700 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA detected at recurrence
Number of subjects: 41
Study 39612700 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal plasma samples
Number of subjects: 41
Study 39612700 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-based MRD detection
Number of subjects: 41
Study 39612700 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD detected within 14 weeks after surgery
Number of subjects: 41
Study 39612724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of adherence based on clinician checklist ratings
Number of subjects: 0
Study 39612724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of competence based on worksheets
Number of subjects: 0
Study 39612724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of adherence based on worksheets
Number of subjects: 0
Study 39612724 — intervention group
Group type: COMPARATOR
Intervention: Observer ratings of adherence and competence
Number of subjects: 0
Study 39612765 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-LCP
Number of subjects: 72
Study 39612765 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 39612767 — intervention group
Group type: EXPERIMENTAL
Intervention: e-book (n = 51)
Number of subjects: 102
Study 39612767 — intervention group
Group type: COMPARATOR
Intervention: video and manual (n = 51)
Number of subjects: 102
Study 39612802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn-MAPS24v (1 μg, 2 μg, or 5 μg per PS)
Number of subjects: 126
Study 39612802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn-MAPS24v
Number of subjects: 126
Study 39612802 — intervention group
Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 126
Study 39612919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m2 weekly) with trastuzumab and pertuzumab
Number of subjects: 689
Study 39612919 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus carboplatin with trastuzumab and pertuzumab
Number of subjects: 689
Study 39612921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ChAdOx1.tHIVconsv1 (C1)
Number of subjects: 13
Study 39612921 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose ChAdOx1.tHIVconsv1 (C1) boosted by MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4)
Number of subjects: 13
Study 39612921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-elicited T-cell frequencies
Number of subjects: 13
Study 39612928 — intervention group
Group type: EXPERIMENTAL
Intervention: Quabodepistat plus delamanid plus bedaquiline
Number of subjects: 44
Study 39612928 — intervention group
Group type: EXPERIMENTAL
Intervention: Quabodepistat plus delamanid
Number of subjects: 44
Study 39612928 — intervention group
Group type: EXPERIMENTAL
Intervention: Quabodepistat plus bedaquiline
Number of subjects: 44
Study 39612928 — intervention group
Group type: COMPARATOR
Intervention: Control (rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy)
Number of subjects: 44
Study 39612928 — intervention group
Group type: EXPERIMENTAL
Intervention: Quabodepistat (all combinations)
Number of subjects: 44
Study 39612947 — intervention group
Group type: EXPERIMENTAL
Intervention: AI digital pathology (DP) platform
Number of subjects: 120
Study 39612953 — intervention group
Group type: COMPARATOR
Intervention: SABR alone
Number of subjects: 69
Study 39612953 — intervention group
Group type: EXPERIMENTAL
Intervention: chemo-SABR
Number of subjects: 69
Study 39613097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (100/200 mg by body weight) every 2 weeks for 52 weeks
Number of subjects: 174
Study 39613097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 39613100 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy in monotherapy
Number of subjects: 1018
Study 39613100 — intervention group
Group type: EXPERIMENTAL
Intervention: LLT combination therapy
Number of subjects: 1018
Study 39613100 — intervention group
Group type: EXPERIMENTAL
Intervention: No lipid-lowering therapy (LLT)
Number of subjects: 1018
Study 39613100 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C goal attainment
Number of subjects: 1018
Study 39613120 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily (n=142)
Number of subjects: 211
Study 39613120 — intervention group
Group type: COMPARATOR
Intervention: Investigator-assigned therapy (IAT) (n=69)
Number of subjects: 211
Study 39613428 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg verapamil administered orally once daily
Number of subjects: 120
Study 39613428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 39613437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.0 ATA for 90 minutes
Number of subjects: 0
Study 39613437 — intervention group
Group type: COMPARATOR
Intervention: Usual care for VOCs (including hydration, analgesics, normobaric oxygen therapy, and when medically indicated, antibiotic therapy and/or transfusions)
Number of subjects: 0
Study 39613746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 0
Study 39613828 — intervention group
Group type: EXPERIMENTAL
Intervention: Call it a Night (CIAN)
Number of subjects: 120
Study 39613828 — intervention group
Group type: COMPARATOR
Intervention: Control (A + SM: web-based advice + self-monitoring or A: advice)
Number of subjects: 120
Study 39614012 — intervention group
Group type: EXPERIMENTAL
Intervention: bpMRI protocol (biparametric MRI)
Number of subjects: 77
Study 39614069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse phone calls focusing on education
Number of subjects: 147
Study 39614069 — intervention group
Group type: COMPARATOR
Intervention: Primary care as usual
Number of subjects: 147
Study 39614147 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one FRID
Number of subjects: 2157
Study 39614147 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple FRIDs (≥ 2 FRIDs)
Number of subjects: 2157
Study 39614235 — intervention group
Group type: EXPERIMENTAL
Intervention: TRE 16:8 (16 hours fasting, 8 hours eating)
Number of subjects: 41
Study 39614235 — intervention group
Group type: EXPERIMENTAL
Intervention: TRE 14:10 (14 hours fasting, 10 hours eating)
Number of subjects: 41
Study 39614235 — intervention group
Group type: EXPERIMENTAL
Intervention: TRE 12:12 (12 hours fasting, 12 hours eating)
Number of subjects: 41
Study 39614235 — intervention group
Group type: COMPARATOR
Intervention: Normal Diet (ND; no dietary restriction)
Number of subjects: 41
Study 39614265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 240
Study 39614265 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 240
Study 39614356 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily average concentrations of PM
Number of subjects: 168
Study 39614356 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily average concentrations of nitrogen dioxide (NO2)
Number of subjects: 168
Study 39614619 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion (ER) identified in 34 patients (49%)
Number of subjects: 70
Study 39614619 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete reperfusion (100% filling of the 55° ICGA field) achieved in 21 patients (30%)
Number of subjects: 70
Study 39614619 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 70
Study 39614707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase inhibitor)
Number of subjects: 75
Study 39614707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 39614707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral pulsatility
Number of subjects: 75
Study 39614707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular reactivity
Number of subjects: 75
Study 39614707 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of WMH
Number of subjects: 75